CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞在惰性淋巴瘤、套细胞淋巴瘤、慢性淋巴细胞白血病中的应用
英文原题：Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia.
查看英文原题
Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T 细胞疗法的出现，改变了多种血液系统恶性肿瘤的治疗格局。初期获益主要见于侵袭性白血病和淋巴瘤，但近期数据已促使多种 CAR-T 疗法获批用于惰性淋巴瘤；持续进行的研究也为进一步改善和优化治疗带来巨大希望。本文综述惰性淋巴瘤 CAR-T 细胞疗法的已发表数据和已获批疗法，重点讨论套细胞淋巴瘤和滤泡性淋巴瘤，并介绍慢性淋巴细胞白血病中的研究及未来策略。
展开英文摘要原文
The advent of chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of several hematological malignancies. Although the initial benefit was mainly observed in aggressive leukemias and lymphomas, recent data have resulted in the approval of multiple CAR-T therapies in indolent lymphomas, with ongoing research showing great promise for further improvements and therapeutic optimizations.
In this article, we review the published data and approved therapies for CAR-T cell therapy for indolent lymphomas focusing on mantle cell lymphoma and follicular lymphoma while describing the work in chronic lymphocytic leukemia and future strategies.
论文信息
- 作者
- Shah PS、Jacobson CA
- 第一作者单位
- Dartmouth Cancer Center, 1 Medical Center Drive, Lebanon, NH 03750, USA.United States
- 通讯作者单位
- Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215-5450, USA. Electronic address: Caron_Jacobson@dfci.harvard.edu.United States
- 文献类型
- 综述
- 期刊
- Hematology/oncology clinics of North America2023 Dec
- 原文标识
- PubMed 37659889 · DOI 10.1016/j.hoc.2023.07.002